Re-analysis of Safety Data Supporting Doxylamine Use for Nausea and Vomiting of Pregnancy

Abstract

Antihistamines are commonly used to treat nausea and vomiting of pregnancy (NVP). We re-analyzed the 24 primary studies cited in a 1997 meta-analysis that concluded antihistamine use for NVP was safe as they had been studied in more than 200,000 participating women and the pooled odds ratio for congenital malformations was 0.76 (95% confidence interval [CI]: 0.60–0.94). Our analysis of this meta-analysis showed that 139,414 women were included in 22 original studies involving antihistamines, 129,108 of which were in studies involving doxylamine. In these studies, 23,485 women were exposed to antihistamines, 14,624 of which were exposed to doxylamine. The summary relative risk (cohort studies) and odds ratio (case–control studies) for congenital malformations from antihistamine exposure were 1.09 (95% CI: 1.01–1.18) and 1.04 (95% CI: 0.91–1.19), and for doxylamine exposure, the summary relative risk and odds ratio were 0.94 (95% CI: 0.80–1.10) and 1.07 (95% CI: 0.93–1.23), respectively. Although not a new systematic review, our re-analysis demonstrates that the safety data for antihistamines, and doxylamine in particular, are based on many fewer than 200,000 participating women and exposures, and that doxylamine use is not associated with a decreased risk of malformations as previously reported.

Keywords

congenital malformations - doxylamine - nausea and vomiting of pregnancy - drug safety

• References

• 1 Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract 1993; 43 (371) 245-248
• 2 Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: a prospective study of its frequency, intensity, and patterns of change. Am J Obstet Gynecol 2000; 182 (4) 931-937
• 3 Briggs G, Freeman RK, Yaffe SJ. Doxylamine. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risks. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011: 4527
• 4 Public Health Agency of Canada. Statement on Pregnancy and Travel; 2010. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-2/index-eng.php . Accessed May 17, 2012
• 5 Arsenault MY, Lane CA, MacKinnon CJ , et al. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can 2002; 24 (10) 817-831 , quiz 832–833
• 6 Einarson A, Maltepe C, Boskovic R, Koren G. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician 2007; 53 (12) 2109-2111
• 7 Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol 1997; 14 (3) 119-124
• 8 Kar S, Krishnan A, Preetha K, Mohankar A. A review of antihistamines used during pregnancy. J Pharmacol Pharmacother 2012; 3 (2) 105-108
• 9 So M, Bozzo P, Inoue M, Einarson A. Safety of antihistamines during pregnancy and lactation. Can Fam Physician 2010; 56 (5) 427-429
• 10 Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002; 186 (5, Suppl Understanding ): S256-S261
• 11 Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and non-pharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000; 59: 781-800
• 12 Ayd Jr FJ. Haloperidol: fifteen years of clinical experience. Dis Nerv Syst 1972; 33 (7) 459-469
• 13 Aselton PJ, Jick H. Additional follow-up of congenital limb disorders in relation to Bendectin use. JAMA 1983; 250 (1) 33-34
• 14 Gibson GT, Colley DP, McMichael AJ, Hartshorne JM. Congenital anomalies in relation to the use of doxylamine/dicyclomine and other antenatal factors: an ongoing prospective study. Med J Aust 1981; 1 (8) 410-414
• 15 Bunde CA, Bowles DM. A technique for controlled survey of case records. Curr Ther Res Clin Exp 1963; 5: 245-248
• 16 Kullander S, Källén B. A prospective study of drugs and pregnancy. II. Anti-emetic drugs. Acta Obstet Gynecol Scand 1976; 55 (2) 105-111
• 17 Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. First-trimester drug use and congenital disorders. JAMA 1981; 246 (4) 343-346
• 18 Golding J, Vivian S, Baldwin JA. Maternal anti-nauseants and clefts of lip and palate. Hum Toxicol 1983; 2 (1) 63-73
• 19 Greenberg G, Inman WHW, Weatherall JAC, Adelstein AM, Haskey JC. Maternal drug histories and congenital abnormalities. BMJ 1977; 2 (6091) 853-856
• 20 Newman NM, Correy JF, Dudgeon GI. A survey of congenital abnormalities and drugs in a private practice. Aust N Z J Gynaecol 1977; 17: 156-159
• 21 General Practitioner Research Group. General Practitioner Clinical Trials: drugs in pregnancy survey . Practitioner 1963; 191: 775-780
• 22 Smithells RW, Sheppard S. Teratogenicity testing in humans: a method demonstrating safety of bendectin. Teratology 1978; 17 (1) 31-35
• 23 Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 1985; 313 (6) 347-352
• 24 Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton MA: PSG Publishing; 1977
• 25 Mellin G, Katzenstein M. Meclozine and fetal abnormalities. Lancet 1963; 26: 222-223
• 26 Milkovich L, van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 1976; 125 (2) 244-248
• 27 Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. BMJ 1971; 1 (5748) 523-527
• 28 Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979; 109 (4) 433-439
• 29 Morelock S, Hingson R, Kayne H , et al. Bendectin and fetal development. A study of Boston City Hospital. Am J Obstet Gynecol 1982; 142 (2) 209-213
• 30 McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 1994; 50 (1) 27-37
• 31 Michaelis J, Gluck E, Michaelis H , et al. Does Lenotan have teratogenic effects?. Dtsch Arzt 1980; 23: 1527-1529
• 32 Shiono PH, Klebanoff MA. Bendectin and human congenital malformations. Teratology 1989; 40 (2) 151-155
• 33 Aselton P, Jick H, Milunsky A, Hunter JR, Stergachis A. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65 (4) 451-455
• 34 Erickson JD. Risk factors for birth defects: data from the Atlanta Birth Defects Case-Control Study. Teratology 1991; 43 (1) 41-51
• 35 Fejzo MS, Ingles SA, Wilson M , et al. High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals. Eur J Obstet Gynecol Reprod Biol 2008; 141 (1) 13-17
• 36 Matthews A, Dowswell T, Haas DM, Doyle M, O'Mathúna DP. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev 2010; (9, Issue 9) CD007575
• 37 Seto A, Einarson T, Koren G. Evaluation of brompheniramine safety in pregnancy. Reprod Toxicol 1993; 7 (4) 393-395
• 38 Nora JJ, Nora AH, Sommerville RJ, Hill RM, McNamara DG. Maternal exposure to potential teratogens. JAMA 1967; 202 (12) 1065-1069
• 39 Fleming DM, Knox JDE, Crombie DL. Debendox in early pregnancy and fetal malformation. Br Med J (Clin Res Ed) 1981; 283 (6284) 99-101
• 40 Michaelis J, Michaelis H, Glück E, Koller S. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology 1983; 27 (1) 57-64
• 41 Eskenazi B, Bracken MB. Bendectin (Debendox) as a risk factor for pyloric stenosis. Am J Obstet Gynecol 1982; 144 (8) 919-924